basic helix-loop-helix family member a15Genealiases: BHLHB8 · MIST1
Q-omics provides the consensus-scored BHLHA15 profile across patient tissues and cancer cell-line models. BHLHA15 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BHLHA15 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, BHLHA15 RNA expression shows 19,932 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRC, and PDAC as cancer lineages where BHLHA15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BHLHA15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BHLHA15 survival associations across molecular data types. BHLHA15 RNA expression shows survival associations in the most cancer types (26), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BHLHA15 RNA expression–survival associations across cancer types. High BHLHA15 expression shows unfavorable associations in UVM, KIRP and CESC, but favorable associations in SKCM, HNSC and SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BHLHA15 RNA expression.
This table summarizes BHLHA15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BHLHA15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BHLHA15 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD, BLCA, UCEC and LIHC. The KIRC box plot shows higher BHLHA15 RNA expression in tumor versus normal tissue (log2 FC = +1.739, t-test p < 0.001).
This table shows molecular features associated with BHLHA15 in patient tissues and cancer cell lines. In patient samples, BHLHA15 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, BHLHA15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
